Tango Therapeutics Stock (NASDAQ:TNGX)

Forecast Revenue Ownership Financials Chart

Previous Close

$6.84

52W Range

$1.03 - $10.81

50D Avg

$6.58

200D Avg

$3.64

Market Cap

$726.53M

Avg Vol (3M)

$1.96M

Beta

1.65

Div Yield

TNGX Company Profile

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

155

IPO Date

Sep 03, 2020

Website

TNGX Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24	Dec 23	Dec 22
License Revenue	$12.10M	$5.00M	-
Collaboration Revenue	$29.97M	$31.53M	$24.86M

Fiscal year ends in Dec 24 | Currency in USD

TNGX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$42.07M	$36.53M	$24.86M
Operating Income	$-145.59M	$-114.17M	$-111.07M
Net Income	$-130.30M	$-101.74M	$-108.18M
EBITDA	$-145.59M	$-111.76M	$-109.46M
Basic EPS	$-1.19	$-1.08	$-1.23
Diluted EPS	$-1.19	$-1.08	$-1.23

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
TCRX	TScan Therapeutics, Inc.
RVMD	Revolution Medicines, Inc.
CCCC	C4 Therapeutics, Inc.
STOK	Stoke Therapeutics, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
GLUE	Monte Rosa Therapeutics, Inc.
ERAS	Erasca, Inc.
TYRA	Tyra Biosciences, Inc.
THRD	Third Harmonic Bio, Inc.